Most cited papers from LFB (United States)

LFB (United States)

What are the most cited papers from LFB (United States)?

The most cited paper from LFB (United States) is "Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO" (Meghan Chlebowski, Sirine A. Baltagi, Mel Carlson et al., 2020), with 207 citations. Next come "Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)" (160) and "Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology" (120).

Published TypeFieldAccessCitations

Showing 50 of 82 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO Meghan Chlebowski, Sirine A. Baltagi, Mel Carlson et al. · Critical Care Open access	20 Jan 2020	207
2	Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) Ulrich Budde et al. · Journal of Thrombosis and Haemostasis Open access	Mar 2008	160
3	Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology Claudine Mazurier, Jenny Goudemand, Lysiane Hilbert et al. · Best Practice & Research Clinical Haematology	Jun 2001	120
4	Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD Jeroen C.J. Eikenboom et al. · Journal of Thrombosis and Haemostasis Open access	15 Mar 2006	119
5	Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Bertrand Godeau, Marie‐Thérèse Caulier, Laurent Decuypere et al. · British Journal of Haematology	Dec 1999	105
6	The transgenic animal platform for biopharmaceutical production L. R. Bertolini, Harry Meade, Cícera Regina Lazzarotto et al. · Transgenic Research	28 Jan 2016	95
7	Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies Mathilde Bas, Aurélie Terrier, Émilie Jacque et al. · The Journal of Immunology	25 Jan 2019	82
8	Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study Jeroen C.J. Eikenboom et al. · Journal of Thrombosis and Haemostasis Open access	30 Jun 2009	61
9	Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody Céline Monnet, Sylvie Jorieux, Nathalie Souyris et al. · mAbs Open access	15 Jan 2014	51
10	Tumor necrosis factor alpha levels in plasma and whole-blood culture in dengue-infected patients: Relationship between virus detection and pre-existing specific antibodies Didier Hober, Trong Lan Nguyen, Lu Shen et al. · Journal of Medical Virology	Mar 1998	49
11	The impact of bleeding history, von Willebrand factor and PFA–100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM‐1VWD Giancarlo Castaman, Alberto Tosetto, Anne C. Goodeve et al. · British Journal of Haematology Open access	25 Aug 2010	48
12	Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti‐D Bertrand Godeau, Éric Oksenhendler, YVES BROSSARD et al. · Transfusion	Apr 1996	47
13	Some Factor VIII (FVIII) Inhibitors Recognise a FVIII Epitope(s) that Is Present only on FVIII-vWF Complexes Renaud Lavend’homme, Kathelijne Peerlinck, Marc G Jacquemin et al. · Thrombosis and Haemostasis	1999	46
14	Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII‐binding capacity Lysiane Hilbert, Sylvie Jorieux, Valérie Proulle et al. · British Journal of Haematology	Feb 2003	45
15	Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents Claudine Caron, Claudine Mazurier, Jenny Goudemand · British Journal of Haematology	19 May 2002	42
16	PERSEPT 1: a phase 3 trial of activated eptacog beta for on‐demand treatment of haemophilia inhibitor‐related bleeding Michael Wang, Jeanne Bentley Lawrence, Doris V. K. Quon et al. · Haemophilia Open access	3 Aug 2017	40
17	The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer Nathalie Kersual, Véronique Garambois, Thierry Chardès et al. · mAbs Open access	22 May 2014	32
18	Comparison between von Willebrand Factor (VWF) and VWF Antigen II in Normal Individuals and Patients with von Willebrand Disease Claudine Mazurier, Christophe de Romeuf · Thrombosis and Haemostasis	1998	30
19	Kinetic analysis and binding studies of a new recombinant human factor VII a for treatment of haemophilia J A Grandoni, Gérald Perret, Cynthia Forier · Haemophilia Open access	19 Dec 2016	19
20	Safety and dose‐dependency of eptacog beta (activated) in a dose escalation study of non‐bleeding congenital haemophilia A or B patients, with or without inhibitors Jonathan M. Ducore, Jeanne Bentley Lawrence, Mindy L. Simpson et al. · Haemophilia Open access	5 Oct 2017	18
21	Human Immunoglobulins in Intraocular Inflammation Z. Tellier · Annals of the New York Academy of Sciences	Sep 2007	18
22	Platelet Activation and Aggregation Induced by Recombinant von Willebrand Factors Reproducing Four Type 2B von Willebrand Disease Missense Mutations Lysiane Hilbert, Claudine Mazurier, Christophe de Romeuf · Thrombosis and Haemostasis	1998	18
23	Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263K scrapie‐infected brain homogenates in “spiked” albumin solutions Franco Cardone, Steve Simoneau, Aude Arzel et al. · Transfusion	14 Nov 2011	17
24	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors Steven W. Pipe et al. · Haemophilia Open access	27 Apr 2022	15
25	On the Mechanism of Plasmin-induced Aggregation of Human Platelets: Implication of Secreted von Willebrand Factor Samia Rabhi-Sabile, Christophe de Romeuf, Dominique Pidard · Thrombosis and Haemostasis	1998	15
26	2 Molecular basis of von Willebrand disease Claudine Mazurier, Dominique Meyer · Baillière s Clinical Haematology	Jun 1996	15
27	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors Miguel Antonio Escobar et al. · Haemophilia Open access	11 Oct 2021	14
28	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors Miguel Antonio Escobar et al. · Haemophilia Open access	6 Oct 2021	13
29	Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk Jianguo Zhao, Weijie Xu, Jason W. Ross et al. · Scientific Reports Open access	21 Sep 2015	13
30	Recommended Abbreviations for von Willebrand Factor and Its Activities Francesco Rodeghiero, Claudine Mazurier · Thrombosis and Haemostasis	2001	13
31	Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease Antoine Hommais, Alain Stépanian, Édith Fressinaud et al. · Thrombosis and Haemostasis	2006	13
32	Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma J A Grandoni, Véronique Duretz, Daniel Bonzo et al. · Haemophilia Open access	6 Feb 2021	12
33	Generation of transgenic goats by pronuclear microinjection: a retrospective analysis of a commercial operation (1995–2012) William G. Gavin, Stephen Blash, N. Buzzell et al. · Transgenic Research	16 Dec 2017	11
34	Sécurité virale des préparations d'immunoglobulines G intraveineuses à usage thérapeutique Thierry Burnouf · Transfusion Clinique et Biologique	1995	11
35	Transgenic goats producing an improved version of cetuximab in milk Götz Laible, Sally Cole, Brigid Brophy et al. · FASEB BioAdvances Open access	15 Aug 2020	10
36	Increased Accumulation and Retention of rhFVIIa (eptacog beta) in Knee Joints of Hemophilia A Mice Compared to Wild-Type Mice Jhansi Magisetty, Usha R. Pendurthi, SubbaRao V. Madhunapantula et al. · Thrombosis and Haemostasis Open access	26 May 2019	10
37	Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines? Carole Rosier, N. Graveline, A. Lacour et al. · European Journal of Neurology	16 Oct 2018	10
38	Johne's disease: a successful eradication programme in a dairy goat herd William G. Gavin, Catherine A. Porter, Nathaniel D. Hawkins et al. · Veterinary Record	8 Feb 2018	9
39	Factor VIII deficiency not induced by FVIII gene mutation in a female first cousin of two brothers with haemophilia A Claudine Mazurier, Armelle Parquet-Gernez, Christine Gaucher et al. · British Journal of Haematology Open access	30 Oct 2002	9
40	Management of Haemophilia A-Inhibitor Patients: Clinical and Regulatory Perspectives Z. Tellier, Marie-Hélène André, Benoı̂t Polack · Clinical Reviews in Allergy & Immunology	27 Jan 2009	9
41	Purification of Human Ceruloplasmin as a By-Product of C1-Inhibitor. Ferdinand Kouoh Elombo, Miryana REDOSEVICH, Michel Poulle et al. · Biological and Pharmaceutical Bulletin Open access	2000	9
42	Induction of parturition in a large number of pregnant dairy goats and its benefits as a management tool in a commercial scale goat operation John M. Pollock, Kerry Miner, N. Buzzell et al. · Theriogenology	24 May 2021	8
43	Passive Immunity to Vibrio cholerae O1 Afforded by a Human Monoclonal IgA1 Antibody Expressed in Milk Danielle E. Baranova, LiHow Chen, Margaret M. Destrempes et al. · Pathogens and Immunity Open access	7 May 2020	8
44	Recommended abbreviations for von Willebrand Factor and its activities. Claudine Mazurier, Francesco Rodeghiero · PubMed	Aug 2001	7
45	Risk–Benefit Analysis of Nucleic Acid Testing: The French Experience Christine Saura, A.M. Couroucé, Josiane Pillonel et al. · Biologicals	Dec 1999	7
46	Generation of goats by nuclear transfer: a retrospective analysis of a commercial operation (1998–2010) William G. Gavin, N. Buzzell, Stephen Blash et al. · Transgenic Research	Jul 2020	6
47	Perspectives Anne Cortey, Yvon Brossard, R. Beliard et al. · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction	Feb 2006	5
48	Drug-Induced “Suspended Animation” Pierre Asfar, Peter Radermacher · Critical Care Medicine	17 Jun 2015	5
49	Transcranial Doppler in the Diagnosis of Cerebral Vasospasm: A Call for a Dynamic Approach Karim Lakhal, Vincent Robert-Edan, Marion Fresco et al. · Critical Care Medicine	30 Jan 2019	4
50	Caprine herpesvirus 1: A successful eradication program in dairy goat herd John M. Pollock, Michael Schofield, Catherine A. Porter et al. · Small Ruminant Research	13 Nov 2018	4

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.